What GeoVax Labs, Inc. does.

GeoVax Labs, Inc. (“GeoVax”, “us”, “we” or the “Company”) is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms.

GeoVax’s primary near-term strategic development priority is the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. GEO-MVA is being advanced on an expedited regulatory pathway in Europe and is intended to address a significant global supply constraint for orthopoxvirus vaccines. The Company believes GEO-MVA is well-positioned to support both civilian public health needs and broader preparedness and biodefense objectives. The advancement of GEO-MVA represents the Company’s most near-term opportunity to achieve regulatory approval and potential commercialization. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026.

The Company’s lead clinical program in oncology is Gedeptin®, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. A Phase 2 clinical trial evaluating Gedeptin® in combination with an immune checkpoint inhibitor (ICI) as first-line treatment of patients with squamous cell head and neck cancer eligible for curative surgery, is planned to initiate during the first half of 2027.

Revenue and profit, by fiscal year.

More on GOVX.

• GeoVax Labs, Inc. summary
• GeoVax Labs, Inc. financial statements
• GeoVax Labs, Inc. key metrics
• GeoVax Labs, Inc. health scores and style box
• GeoVax Labs, Inc. earnings
• GeoVax Labs, Inc. dividends
• GeoVax Labs, Inc. valuation
• GeoVax Labs, Inc. ownership and insiders
• GeoVax Labs, Inc. peers

Figures from GeoVax Labs, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.